HENAN TALOPH PHARMACEUTICAL STOCK CO.,LTD

Henan Taloph Pharmaceutical Stock Co.,Ltd

600222

CNE0000010L8

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-07-14 pm EDT			5-day change	1st Jan Change
4.25 ^CNY	-2.07%		+0.95%	-30.67%

Apr. 25	Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 02	Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on February 2, 2024.	CI

Henan Taloph Pharmaceutical Stock Co., Ltd. Provides Earnings Guidance for the Year 2012

January 19, 2013

Henan Taloph Pharmaceutical Stock Co., Ltd. provided earnings guidance for the year 2012. The company predicts a year-on-year increase of over 50% in the net profit belonging to owners of parent company in 2012.

Latest news about Henan Taloph Pharmaceutical Stock Co.,Ltd

Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on February 2, 2024.	Apr. 01	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd announces an Equity Buyback for CNY 60 million worth of its shares.	Feb. 01	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd authorizes a Buyback Plan.	Jan. 31	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Henan Taloph Pharma Receives 41 Million Yuan in Government Grants in Q3	23-10-09	MT
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-18	CI
Taloph Pharmaceutical Gets Nod to Amend License of Three Products	23-07-21	MT
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on July 15, 2022.	23-07-13	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback announced on July 15, 2022, has closed with 14,523,100 shares, representing 2.57% for CNY 79.72 million.	23-07-12	CI
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on July 15, 2022.	23-07-03	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-06	CI
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on July 15, 2022.	23-03-31	CI
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on July 15, 2022.	23-01-03	CI
Henan Taloph Pharma Vice Chairman Resigns; Shares Slump 10%	22-12-19	MT
Tailong Health Industry Investment Co., Ltd announced that it expects to receive CNY 220 million in funding from Henan Taloph Pharmaceutical Stock Co.,Ltd	22-11-09	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Tranche Update on Henan Taloph Pharmaceutical Stock Co.,Ltd's Equity Buyback Plan announced on July 15, 2022.	22-10-10	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-19	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd announces an Equity Buyback for CNY 80 million worth of its shares.	22-07-14	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd authorizes a Buyback Plan.	22-07-13	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd(SHSE:600222) added to Shanghai Stock Exchange Composite Index	22-05-09	CI
Henan Taloph Pharmaceutical Stock Co.,Ltd(SHSE:600222) dropped from Shanghai Stock Exchange Composite Index	22-05-05	CI

Chart Henan Taloph Pharmaceutical Stock Co.,Ltd

Duration

Period

Chart Henan Taloph Pharmaceutical Stock Co.,Ltd

More charts

Company Profile

Henan Taloph Pharmaceutical Stock Co Ltd is a China-based company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. The Company operates four segments. Pharmaceutical Manufacturing segment is mainly engaged in pharmaceutical preparations and Chinese herbal medicine slices business. Its products include Shuanghuanglian oral liquid series, Shuangjinlian mixture, Xiaoer Qingre Zhike oral liquid, Xiaoer Tuire oral liquid, Danshen oral liquid, Shengmaiyin, Fufang Yimu oral liquid, and various Chinese herbal medicine slices. Pharmaceutical and Medicinal Materials Circulation segment is mainly engaged in fresh processing business and traceable medicinal materials trading. Pharmaceutical Research and Development Services segment mainly provides technical services such as preclinical pharmaceutical research, clinical contract research organization (CRO) research, and registration application. Other segment is mainly engaged in investment business.

Sector

Pharmaceuticals

Calendar

2024-08-21 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HENAN TALOPH PHARMACEUTICAL STOCK CO.,LTD	-30.67%	327M
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+39.02%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ASTRAZENECA PLC	+13.87%	244B
ROCHE HOLDING AG	+4.99%	234B
NOVARTIS AG	+16.30%	226B
AMGEN INC.	+14.63%	177B